Genzyme Corp.'s longstanding legal dispute with some shareholders over the buyback of Genzyme Biosurgery stock in 2003 will end not with a figurative bang but with a $64 million whimper, if a judge approves an agreement made between the parties. (BioWorld Today)

July's death of a patient in Targeted Genetics Inc.'s halted Phase I/II trial of the arthritis drug tgAAC94 shone the spotlight - unfavorably, again - on gene therapy, dragging all involved companies out for inspection. And it gave many investors an excuse to talk about China, as if many in biotech weren't already. (BioWorld Financial Watch)